TrialPath
Recruiting

DBS and Levodopa for Treating Freezing of Gait in Parkinson's Disease

NCT06316232 · IRCCS Istituto delle Scienze Neurologiche di Bologna
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Efficacy of Deep Brain Stimulation and Levodopa on Freezing of Gait in Advanced Parkinson's Disease: a Comparative Study
About this study
This is a cross-over, blind, randomized study to evaluate the improvement of FoG in a group of PD patients treated with bilateral STN-DBS by increasing the intensity of stimulation (STIM plus) or administering a higher dose of levodopa (MED plus). Patient will be videorecorded for evaluation of freezing episodes and gait cinematic parameters by means of 3 wearable inertial sensors on the feet and at lumbar level during a standardized walking protocol including: Timed Up and Go, Turn 360°, Gait 18 m and a Complex task in single task and dual task (serial-3 subtractions) conditions. In each condition, Tinetti scale, Trail Making Test, alternate fluency test, Movement Disorders Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) and MDS Unified Dyskinesia Rating Scale (UDysRS) will be also perform. In addition, other demographic and clinical information such as age, sex, MMSE, MoCA, New Freezing of Gait Questionnaire, Falls Efficacy Scale will be collected. The primary endpoint of this study is to investigate the efficacy of increasing intensity of stimulation (STIM plus) or levodopa (MED plus) on freezing of gait (FOG). Secondary outcome measures include cinematic gait parameters, global motor outcomes and cognitive functions.
Eligibility criteria
Inclusion Criteria: * Patients with Parkinson's disease treated with STN-DBS who achieved a good control of motor fluctuations and cardinal motor symptoms (bradykinesia, rigidity, tremor) * History of FoG in daily-ON condition after optimal DBS programming, defined by a score of 1 on Question 1 and score ≥ 2 on Question 2 of the New Freezing of Gait Questionnaire. Exclusion Criteria: * inability to walk independently for 10 meters. * limited therapeutic windows of stimulation without the possibility of increase the intensity of stimulation of 0,5 mA for the appearance of side effects * previous evidence of severe adverse effects with high levodopa dose ore increased STN-DBS intensity, such as psychosis, hallucinations, painful dyskinesias, severe hypotension, digestive symptoms. * dementia (MMSE score ≤ 18)
Study design
Enrollment target: 20 participants
Allocation: randomized
Masking: single
Age groups: adult, older_adult
Timeline
Starts: 2023-10-10
Estimated completion: 2026-12-31
Last updated: 2024-03-18
Interventions
Device: STIM ON plusDrug: MED ON plus
Primary outcomes
  • • Time spent with FOG during protocol (immediate post monitoring)
Sponsor
IRCCS Istituto delle Scienze Neurologiche di Bologna · other
With: A.O.U. Città della Salute e della Scienza
Contacts & investigators
ContactIlaria Cani · contact · ilaria.cani@studio.unibo.it · 0039 051 4966959
ContactGiulia Giannini · contact · giulia.giannini15@unibo.it · 0039 051 4966959
InvestigatorIlaria Cani · principal_investigator, IRCCS Istituto delle Scienze Neurologiche di Bologna
All locations (1)
IRCCS Istituto delle Scienze Neurologiche di BolognaRecruiting
Bologna, Italy